Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses - Wikidata - awgldk - TriplyDB

Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses

Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses

http://www.wikidata.org/entity/Q36539394

about

Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus Neutralizing antibody response and SARS severity Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2.Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.Mucosal vaccines against respiratory syncytial virus Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1 Current concepts and progress in RSV vaccine development.Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains Neonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infants Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice.Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Respiratory syncytial virus--a comprehensive review.Central nervous system alterations caused by infection with the human respiratory syncytial virus.Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis.Inhibition of Respiratory Syncytial Virus Replication by Simultaneous Targeting of mRNA and Genomic RNA Using Dual-Targeting siRNAs.Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.

P2860

Q27010165-9763D148-26C1-4765-934C-6949870C1C2F Q27021304-E8E08917-96CD-45D7-8EC8-1794F0FC54AC Q28067143-C088EA2C-FC01-4CA1-978F-4D8CE2BDFAA0 Q28385241-075EBB6E-CC87-4D06-88FC-BDC0160AEC78 Q30425776-CBB9A963-87BD-4B35-B3D6-B6A203D9EF99 Q30485791-684DCCD4-9AE7-41D1-B2F3-B4FCB1317842 Q33813095-17E8DA8E-BF24-46CA-B9DF-CC16E744D1B7 Q33837530-E66A759E-5F21-46BF-8AE7-618EDB4C9E55 Q33964142-1AE4AE4D-7D95-4E2B-9F55-8CC3A6FDF0B9 Q34175747-A2C600D2-F382-4A29-949F-FAE99EB5342F Q34396689-C8961176-342E-4563-9C0A-7ED0186FEE93 Q34661842-1B5EFB8C-A4A7-4702-9ABE-141A86A65D2C Q35690781-8BC0F69C-818A-4DE1-9B6A-D7FD2054EE5A Q36363325-EF83EA4F-BE30-42C0-9899-D5CF7E96B087 Q36482799-0F1688AB-B69B-4ED4-9196-625EE84FC3D2 Q36483809-432DE38F-1B7D-4B79-A1CA-47E758E8BB8B Q36530226-789A2DEC-082D-464A-8A05-471E5983D15B Q36810987-54255BEC-915B-452C-878C-AC415A1031C0 Q36947774-9734048C-B177-480A-AC69-13E430F5E43F Q37071608-EFB44716-1086-45DC-8BDB-0937ADF12919 Q37412509-F83700AD-2629-4E70-AC56-523C5F1FA09E Q37615056-8DB6F7EF-57B4-4674-9231-9FC68D26346D Q38068469-FF62B2FC-42A9-4B83-A926-824630C2CE8C Q38098094-0E8E1046-7C70-4CD6-8CBE-FAF3D20396D4 Q38260281-5281DB82-583D-436C-A81D-60D356AF5D87 Q39027049-2D3398B6-E4D6-44CA-B5A2-D48662C86A4B Q40021220-C36598BC-06AE-4F73-AA36-52E216E599E6 Q40476115-2F0A8555-DEF4-4051-A6CA-73FE2E4ADE50 Q52649839-B9E4C740-79C9-4608-8AAE-4A107D6D4F06

P2860

Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses

http://www.wikidata.org/entity/Q36539394

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Inability to evoke a long-last ...... ctive nasal antibody responses

@ast

Inability to evoke a long-last ...... ctive nasal antibody responses

@en

type

label

Inability to evoke a long-last ...... ctive nasal antibody responses

@ast

Inability to evoke a long-last ...... ctive nasal antibody responses

@en

prefLabel

Inability to evoke a long-last ...... ctive nasal antibody responses

@ast

Inability to evoke a long-last ...... ctive nasal antibody responses

@en

P1433

Q36539394-D8331F5A-3CFF-4241-9805-578ED103A00A

P1476

Q36539394-6963F173-C0BF-4234-BFE7-28EE059EBE98

P2093

Q36539394-0E73027F-6B7F-46AE-81F7-BD41E09FE54D

Q36539394-754C6FFD-7015-48AE-ADBC-B64441EAB16B

Q36539394-8A0652F5-ABE7-4081-AE51-C42DF9BA8444

Q36539394-AFB27623-B837-4BAA-8E6E-D350A8F8D37C

P2860

Q36539394-092503E2-54BD-4B64-BFC6-BB7899A26C46

Q36539394-0EBB02DD-CE13-4769-A17A-95F337ACB43A

Q36539394-0F28A5F5-9D34-4D73-BDCA-FF5283F57E77

Q36539394-134F58A0-11F6-43F6-9A0E-B7D6F0B6436A

Q36539394-1500E1C1-655A-4591-AD01-2F4FECFB18FF

Q36539394-1EA7B278-8E5D-4928-91A0-AD17D2EA01D9

Q36539394-200BCA6C-76E2-4467-A00A-A5261D80D2EC

Q36539394-2079B5F0-F9C3-4A96-9398-275855FB1CFB

Q36539394-215C6AA7-30FB-4C46-ADED-7A5588452C70

Q36539394-27596F61-05E1-4E68-8ECD-35885ED15419

P304

Q36539394-B16C6C5C-5A9D-4395-B140-7B979CB46B48

P31

Q36539394-E0CA8F81-C4D1-4D8D-9549-352CE79641B8

P356

Q36539394-60259F0C-A451-4F6A-B94B-3CE01A2E89A1

P407

Q36539394-AC589EEA-3D3B-4002-BA0A-9E794B1835A2

P433

Q36539394-E38E1D97-766E-4701-B9A6-654116E7874E

P478

Q36539394-BAF38F6F-6E83-4973-A6A9-04CEEB570BAF

P577

Q36539394-7798EB52-2661-4168-9FE7-866974595DBE

P698

Q36539394-C2DC755A-2CD5-4FE9-B379-BEA5428127DD

P932

Q36539394-A0AA3AE1-58F4-491A-9146-CF4475328A7E

P356

JVI.77.21.11303-11311.2003

P1433

Journal of Virology

P1476

Inability to evoke a long-last ...... ctive nasal antibody responses

@en

P2093

Lisa Hyland

http://www.w3.org/2001/XMLSchema#string

Nathalie Etchart

http://www.w3.org/2001/XMLSchema#string

Richard Singleton

http://www.w3.org/2001/XMLSchema#string

Sam Hou

http://www.w3.org/2001/XMLSchema#string

P2860

Relative importance of rotavirus-specific effector and memory B cells in protection against challenge.

Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract.

Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus.

Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice.

Synergistic upregulation of interleukin-8 secretion from pulmonary epithelial cells by direct and monocyte-dependent effects of respiratory syncytial virus infection.

Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection.

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Influence of maternal antibodies on neonatal immunization against respiratory viruses.

Respiratory syncytial virus infections in children.

P304

11303-11311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.77.21.11303-11311.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14557616

http://www.w3.org/2001/XMLSchema#string

P932

229280

http://www.w3.org/2001/XMLSchema#string